Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Chromocell Therapeutics Corporation (CHRO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/02/2025: CHRO (3-star) is a STRONG-BUY. BUY since 43 days. Simulated Profits (36.12%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 149.56% | Avg. Invested days 57 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.90M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 1 | Beta - | 52 Weeks Range 4.50 - 38.00 | Updated Date 09/3/2025 |
52 Weeks Range 4.50 - 38.00 | Updated Date 09/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -188.95% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 70572046 | Price to Sales(TTM) - |
Enterprise Value 70572046 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.58 | Shares Outstanding 6595850 | Shares Floating 2561300 |
Shares Outstanding 6595850 | Shares Floating 2561300 | ||
Percent Insiders 53.87 | Percent Institutions 13.6 |
Upturn AI SWOT
Chromocell Therapeutics Corporation
Company Overview
History and Background
Chromocell Therapeutics Corporation is a privately held biotechnology company. Founded in 2002, they focus on developing novel therapeutics and screening technologies. Key milestones include securing funding, establishing partnerships, and advancing their product pipeline.
Core Business Areas
- Taste Platform: Focuses on developing novel therapeutics for taste disorders and food ingredients that enhance flavor and reduce salt, sugar, and fat.
- Drug Discovery: Utilizes high-throughput screening of sensory neurons to identify new drug candidates for pain and other neurological disorders.
Leadership and Structure
Details on leadership team and organizational structure are not publicly available as Chromocell is a private company.
Top Products and Market Share
Key Offerings
- Taste modulators: Chromocell's taste modulators, aiming to reduce salt/sugar intake, compete with ingredients from companies like DSM and Ingredion. Market share data not publicly available due to proprietary nature and Chromocell's private status. Revenue data is also proprietary. Competitors in this space include Kerry, Firmenich, and Givaudan.
- Drug Discovery platform: This platform competes with various drug discovery technologies, from traditional methods to AI-driven approaches. The platform identifies drug candidates for pain management and neurologic disorders, competing with companies like Vertex Pharmaceuticals (VRTX) and Biohaven Pharmaceutical. Market share data is not available.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive and rapidly evolving, characterized by intense research and development efforts. Demand for innovative therapeutics, especially in areas like pain management and taste modification, is high.
Positioning
Chromocell positions itself as an innovator in sensory neuron-based drug discovery and taste modulation, leveraging its proprietary technology to identify novel therapeutic targets and ingredients.
Total Addressable Market (TAM)
The TAM for pain management and taste modification is substantial, estimated in the billions of dollars. Chromocell is positioned to capture a share of this market through its innovative approach.
Upturn SWOT Analysis
Strengths
- Proprietary sensory neuron-based technology platform
- Potential for novel drug candidates and food ingredients
- Experienced scientific team
- Strategic partnerships
Weaknesses
- Limited financial resources as a private company
- High research and development costs
- Regulatory hurdles for drug approval
- Competition from larger, more established companies
Opportunities
- Expanding into new therapeutic areas
- Partnering with larger pharmaceutical and food companies
- Securing additional funding
- Developing new applications for its technology platform
Threats
- Failure to secure regulatory approval for drug candidates
- Competition from other biotechnology companies
- Changes in the regulatory environment
- Economic downturn
Competitors and Market Share
Key Competitors
- Vertex Pharmaceuticals (VRTX)
- Biohaven Pharmaceutical (now part of Pfizer (PFE))
- Kerry
- Firmenich
- Givaudan
Competitive Landscape
Chromocell possesses a specialized niche within sensory-based drug discovery, offering it a competitive advantage compared to firms with more general offerings. Larger companies have greater resources but lack the specific focus of Chromocell's technology.
Growth Trajectory and Initiatives
Historical Growth: Growth data is not publicly available.
Future Projections: Future projections are unavailable without financial data.
Recent Initiatives: Recent initiatives include advancing their product pipeline and securing partnerships.
Summary
Chromocell Therapeutics Corporation is a privately held biotech company focusing on sensory-based drug discovery. It has a proprietary technology platform and is advancing its pipeline. However, being a private company, it lacks financial transparency and competes with larger public companies. Securing funding and partnerships is crucial for its growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Market Research Reports
- SEC Filings of Competitors
Disclaimers:
Information is based on publicly available data and best estimates. Market share data is approximate. Analysis is for informational purposes only and not investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Chromocell Therapeutics Corporation
Exchange NYSE MKT | Headquaters Freehold, NJ, United States | ||
IPO Launch date 2024-02-16 | President, CEO, CFO, Treasurer, Secretary & Director Mr. Francis Knuettel II, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://channeltherapeutics.com |
Full time employees 4 | Website https://channeltherapeutics.com | ||
Channel Therapeutics Corporation, a clinical-stage biotech company, develops and commercializes new therapeutics to alleviate pain. It targets sodium ion-channel NaV1.7; and develops NaV blockers that target the body's peripheral nervous system. The company's lead compound is CC8464, which has completed Phase 1 clinical trials for the treatment of moderate-to-severe pain in erythromelalgia and idiopathic small fiber neuropathy. It also develops CT2000 as a topical agent for the treatment of both acute and chronic eye pain; and CT3000 to treat post operative pain with the use of nerve blocks. The company was Chromocell Therapeutics Corporation and changed its name to Channel Therapeutics Corporation in November 2024. Channel Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.